VYNE Therapeutics Inc. Income Statement
VYNE|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
VYNE Therapeutics Inc. reported $501,000 in revenue and $40M in net loss for FY2025. Revenue has declined at a 32.6% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $501.0K | $424.0K | $477.0K | $931.0K | $21.0M | $3.6M | $0 | $0 |
| Cost of Revenue | - | - | - | - | $1.4M | $0 | - | - |
| SG&A Expense | $13.2M | $13.4M | $16.4M | $20.3M | $89.5M | $14.0M | $5.2M | $3.8M |
| R&D Expense | $30.9M | $16.3M | $18.4M | $19.5M | $43.5M | $64.5M | $29.0M | $11.3M |
| Operating Income | -$43.6M | -$29.3M | -$34.3M | -$38.9M | -$252.5M | -$74.9M | -$29.6M | -$14.3M |
| Interest Expense | - | - | - | $5.6M | $4.4M | $0 | - | - |
| Income Tax | $4.0K | $0 | $13.0K | -$448.0K | -$258.0K | $212.0K | $0 | - |
| Net Income | -$39.8M | -$28.5M | -$23.2M | -$73.3M | -$255.6M | -$74.2M | -$29.1M | -$14.1M |
| EPS (Basic) | -$0.93 | -$2.78 | -$7.28 | -$25.64 | $7.88 | - | - | - |
| EPS (Diluted) | -$0.93 | -$2.78 | -$7.28 | -$25.64 | $7.88 | $11.47 | -$5.69 | -$2.82 |
| Shares Outstanding | 14.8M | 14.1M | 3.2M | 3.0M | 43.2M | 9.1M | 23.2M | 5.3M |
| Operating Margin | -8710.0% | -6900.5% | -7189.7% | -4179.5% | -1203.0% | -2083.2% | - | - |
| Profit Margin | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% | -2062.9% | - | - |